Skip to main content

Trump calls for US to cut off trade with Spain over NATO funding, Iran, again seeks control of Greenland at NATO summit

Pedro Sanchez, Spain’s prime minister attends the NATO summit on July 08, 2026 in Ankara, Turkey. (Burak Kara/Getty Images)

(ANKARA, Turkey) — President Donald Trump on Wednesday appeared to grow increasingly frustrated with NATO allies for not supporting his war effort in Iran, targeting Spain in particular and calling for “all trade” to be cut off with that country.

“Spain is a wasted cause,” Trump said at the NATO Summit in Ankara, Turkey, during an official greeting with Secretary General Mark Rutte. “We don’t want to do any trade business with Spain anymore. By the way, I’d like you to cut it up. Scan, Spain is a terrible partner in NATO. They don’t participate, they don’t pay. I don’t want anything to do with Spain. Cut off all trade with Spain, please, including visits.”

The comments were the latest complaint from Trump against Spain, the only member of the North Atlantic Treaty Organization that has not committed to defense spending equal to 5% of its GDP by 2030.

The U.S., because of its outsized military spending, indirectly contributes more to the NATO than any other country, Trump said last week. The U.S. is responsible for about 15% of NATO’s direct funding, according to the bloc.

At last year’s NATO summit at The Hague, allies agreed at Trump’s prompting to target defense spending equal to 5% of each NATO member countries’ GDP, up from the previous 2%. Spain was alone among the 32 member states in saying it wouldn’t commit to the target.

Trump has previously threatened to end trade with Spain, including in March, when the Spanish foreign minister said at the time that they wouldn’t allow the U.S. to use jointly operated bases in southern Spain for any strikes not covered by the U.N.’s charter.

“I don’t want to do any more trade with them. All right, take it immediately,” Trump said on Wednesday. “Don’t even talk to them, they’re hopeless, bad people, because you know they have everybody else going and paying and working in Spain, in particular Spain, there are a couple of others, but in particular Spain, they’re open about it, they’re hostile about it, and let’s see how hostile they remain when they call up, and they ‘please, please, we want to trade with you, sir, we want to trade with you, sir.’ They make so much money with us, and we’re going to see that they make a lot less. I want no business with them.”

After Trump’s comments, sources at Moncloa Palace, the Spanish prime minister’s office, told Madrid’s El Dario newspaper that Spain “maintains an excellent social, cultural, and economic relationship with the U.S., and it is not our intention for that to change.”

Trump on Wednesday said “nobody,” aside from the “small countries” wanted to help the U.S. in its war with Iran.

“There was calls made a few weeks ago,” Trump said, claiming he spoke with the United Kingdom, Germany and France, among others. “Nobody wanted to help. Some of the very small countries wanted to help, because they’re the most vulnerable. I mean, that’s the only reason they wanted to help.”

The leaders of the U.K., France and Germany did not immediately respond to Trump’s statement on Wednesday. Each has repeatedly declined to involve their countries directly in the war, although each also has said Iran should not be allowed to develop nuclear weapons.

Trump spoke about his displeasure with NATO allies at large, saying that the U.S. has paid for allies to be protected against Russia but that safety has “nothing to do” with the U.S.

“They weren’t there for us, and we’ve been there for them, ” he said. “We spent over a trillion dollars over the last short period, trillion in order to protect these countries from Russia, and has nothing to do with us. We have a notion, but it’s been a long-term thing, and they haven’t treated us right.”

Trump on Wednesday shook hands with Danish Prime Minister Mette Frederiksen, a day after the president renewed his calls for the U.S. to take control of Greenland, which is an autonomous territory under Denmark.

Frederiksen pledged earlier in the summit to defend Greenland, saying, “Our position is clear as it has been all through. Greenland is, of course, not for sale.”

Rutte later celebrated Trump’s ability to get allies to pay a greater share for defense. Rutte appeared to remind the U.S. president that Spain was a part of the coalition that upped their spending.

“And you mentioned Spain, even you got Spain to pay 2% they spent, they made a huge step in last year, so there are still issues we have to solve, but hey, also, even Spain, I would say they got to the 2%,” Rutte said.

Copyright © 2026, ABC Audio. All rights reserved.

Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed.The combination treatment regimen pairs the personalized vaccine with Merck's Keytruda, which had previously been used to treat the cancer alone.The treatment showed a 49% reduction of melanoma return after patients underwent surgery and a 59% reduction of metastasization of the cancer to distant organs.Key questions surrounding regulatory review of the vaccine remain.The Food and Drug Administration has not yet approved the vaccine. The agency will review the full data once it has been collected and submitted.While the FDA has already approved other cancer vaccines, this new treatment represents a step forward in the field as it uses mRNA technology and personalized treatment for each patient.Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators on filing submissions for approval of the regimen, the companies said in a joint press release.Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that he expects the treatment to be approved based on very positive trial results and made available to patients likely by early 2027.The vaccine uses genetic information from patients' individual tumors to identify and attack the cancer."It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself," Tarhini said.Melanoma is the deadliest form of skin cancer, with about 112,000 new cases expected in 2026, according to the American Cancer Society.The treatment is considered relatively safe, according to the companies. The most common side effects include fatigue, sore arm and chills.Treatments utilizing mRNA technologies are being used in trials for other forms of cancer, including that of the bladder, kidney, lungs, stomach and pancreas, according to Tarhini."I think it will certainly improve the outcome of our patients," Tarhini said. "We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."Copyright © 2026, ABC Audio. All rights reserved.
Read Next Story